GLMD news & sentiment — Galmed Pharmaceuticals Ltd.

APR 9·TipRanksMed

Galmed Unveils Brain-Penetrant Aramchol Formulation, Expanding Flagship Drug Into CNS Diseases

Galmed Pharmaceuticals announced a new brain-penetrant formulation of its drug Aramchol, co-developed with Barcode Nanotech. This new formulation, delivered via lipid nanoparticles, can cross the blood-brain barrier and is intended to treat synucleinopathies like Parkinson's disease. The development expands Aramchol's potential from liver diseases into high-unmet-need Central Nervous System indications, leveraging AI-enabled screening for optimal delivery.

MAR 4·Stock Titan

Galmed Pharmaceuticals (GLMD) adjourns shareholder meeting and resets date

Galmed Pharmaceuticals Ltd. (GLMD) has adjourned its Special General Meeting of Shareholders due to a lack of quorum. The meeting, originally scheduled for March 4, 2026, will now reconvene on March 5, 2026, at 4:00 p.m. Israel time at the offices of Meitar Law Offices. This information has been incorporated by reference into the company's existing Form S-8 and Form F-3 registration statements.

APR 28·Benzinga

Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook - CG Oncology ( NASDAQ:CGON ) , Galmed Pharmaceuticals ( NASDAQ:GLMD )

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 200 points on Monday. The Dow traded down 0.27% to 40,004.11 while the NASDAQ fell 1.19% to 17,175.43. The S&P 500 also fell, dropping, 0.72% to 5,485.36. Financial shares jumped by 0.6% on Monday.

$GLMD

Galmed Unveils Brain-Penetrant Aramchol Formulation, Expanding Flagship Drug Into CNS Diseases

Galmed Pharmaceuticals (GLMD) adjourns shareholder meeting and resets date

Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook - CG Oncology ( NASDAQ:CGON ) , Galmed Pharmaceuticals ( NASDAQ:GLMD )

News on $GLMD